Metis Biosciences

Metis Biosciences is a private early-stage biopharmaceutical company focused on developing a fundamentally new class of antibiotics for drug-resistant infections. Publicly available company materials describe the business as being uniquely positioned to advance lead compounds against antimicrobial-resistant bacterial pathogens, but they do not disclose a detailed clinical pipeline or named product candidates. The company appears to operate from Santa Cruz, California and remains active as a private corporation. Based on the limited public disclosure available, Metis Biosciences is best characterized as a preclinical anti-infectives biotech centered on novel antibacterial therapeutics.